Last reviewed · How we verify
Pioglitazone vs Metformin
This is a comparative analysis of two marketed diabetes drugs: pioglitazone (a thiazolidinedione that increases insulin sensitivity) versus metformin (a biguanide that reduces hepatic glucose production and improves insulin sensitivity).
This is a comparative analysis of two marketed diabetes drugs: pioglitazone (a thiazolidinedione that increases insulin sensitivity) versus metformin (a biguanide that reduces hepatic glucose production and improves insulin sensitivity). Used for Type 2 diabetes mellitus (both agents), Pioglitazone: insulin resistance, metabolic syndrome, Metformin: prediabetes, polycystic ovary syndrome (off-label).
At a glance
| Generic name | Pioglitazone vs Metformin |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Drug class | Antidiabetic agents (thiazolidinedione vs. biguanide) |
| Target | Pioglitazone: PPAR-γ; Metformin: AMPK |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity in muscle and adipose tissue. Metformin primarily works by activating AMP-activated protein kinase (AMPK), reducing hepatic gluconeogenesis and improving peripheral glucose uptake. Both are first-line agents for type 2 diabetes but differ in mechanism, side effect profile, and clinical outcomes.
Approved indications
- Type 2 diabetes mellitus (both agents)
- Pioglitazone: insulin resistance, metabolic syndrome
- Metformin: prediabetes, polycystic ovary syndrome (off-label)
Common side effects
- Pioglitazone: weight gain
- Pioglitazone: fluid retention / edema
- Pioglitazone: increased fracture risk
- Metformin: gastrointestinal disturbance (nausea, diarrhea)
- Metformin: vitamin B12 deficiency
- Metformin: lactic acidosis (rare)
Key clinical trials
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis (PHASE4)
- Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke (PHASE2)
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (PHASE4)
- Trial for People With Established Type 2 Diabetes During Ramadan (PHASE4)
- Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: